(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 10.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Ionis Pharmaceuticals's revenue in 2025 is $966,956,000.On average, 26 Wall Street analysts forecast IONS's revenue for 2025 to be $148,093,187,520, with the lowest IONS revenue forecast at $137,305,692,946, and the highest IONS revenue forecast at $156,927,270,914. On average, 26 Wall Street analysts forecast IONS's revenue for 2026 to be $150,877,527,336, with the lowest IONS revenue forecast at $109,023,344,184, and the highest IONS revenue forecast at $193,073,476,456.
In 2027, IONS is forecast to generate $225,144,406,270 in revenue, with the lowest revenue forecast at $164,565,983,288 and the highest revenue forecast at $336,906,737,440.